Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-28T17:17:10.112Z Has data issue: false hasContentIssue false
  • English
  • Français

The mechanism of action of zopiclone

Published online by Cambridge University Press:  16 April 2020

A Doble ,
T Canton ,
C Malgouris ,
JM Stutzmann ,
O Piot ,
MC Bardone ,
C Pauchet  and
JC Blanchard
A Doble
Affiliation:
Biology Department, Rhône-Poulenc Korer SA, 13 quai Jules-Guesde, 94403Vitry-sur-Seine, France
T Canton
Affiliation:
Biology Department, Rhône-Poulenc Korer SA, 13 quai Jules-Guesde, 94403Vitry-sur-Seine, France
C Malgouris
Affiliation:
Biology Department, Rhône-Poulenc Korer SA, 13 quai Jules-Guesde, 94403Vitry-sur-Seine, France
JM Stutzmann
Affiliation:
Biology Department, Rhône-Poulenc Korer SA, 13 quai Jules-Guesde, 94403Vitry-sur-Seine, France
O Piot
Affiliation:
Biology Department, Rhône-Poulenc Korer SA, 13 quai Jules-Guesde, 94403Vitry-sur-Seine, France
MC Bardone
Affiliation:
Biology Department, Rhône-Poulenc Korer SA, 13 quai Jules-Guesde, 94403Vitry-sur-Seine, France
C Pauchet
Affiliation:
Biology Department, Rhône-Poulenc Korer SA, 13 quai Jules-Guesde, 94403Vitry-sur-Seine, France
JC Blanchard
Affiliation:
Biology Department, Rhône-Poulenc Korer SA, 13 quai Jules-Guesde, 94403Vitry-sur-Seine, France
Get access

Summary

The mechanism of action of the cyclopyrrolone hypnotic drug zopiclone involves allosteric modulation of the GABAA receptor. Zopiclone displaces the binding of [3H]-flunitrazepam with an affinity of 28 nM, and enhances the binding of the channel blocker [35S]-TBPS. The binding of zopiclone, unlike that of hypnotic benzodiazepines, is not facilitated by GABA. Zopiclone does not distinguish between GABAA receptors containing different α-subunits (BZ1 and BZ2 phenotype). Studies with protein-modifying agents (eg diethylpyrocarbonate) and photoaffinity labelling suggest that cyclopyrrolones bind to a domain on the GABAA receptor different from the benzodiazepine binding domain. The consequence of this interaction with the GABAA receptor is to potentiate responses to GABA, as can be demonstrated by electrophysiological methods. Subchronic treatment of mice with high doses of zopiclone does not produce the changes in sensitivity of the GABAA receptor that are observed with hypnotic benzodiazepines.

Keywords

zopicloneGABAbenzodiazepinedependencephotoaffinity labelling
Type
Research Article
Information
European Psychiatry , Volume 10 , Issue S3: Satellite Symposium to the AEP Congress , 1995 , pp. 117s - 128s
Copyright
Copyright © Elsevier, Paris 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ansseau, MOlie, JPVon Frenckell, RJourdain, GStehlé, BGuillet, PControlled comparisons in the efficacy and safety of four doses of suriclone, diazepam and placebo in generalised anxiety disorder. Psychopharmacology 1991; 104: 439–43CrossRefGoogle Scholar
Battersby, MKRichards, JGMönier, HBenzodiazepine receptor photoaffmity labelling and localisation. Eur J Pharmacol 1979; 57: 277–78Google Scholar
Blanchard, JCJulou, LSuriclone —a new cyclopyrrolone derivative recognising receptors labelled by benzodiazepines in rat hippocampus and cerebellum. J Neurochem 1983; 40: 601–7CrossRefGoogle Scholar
Blanchard, JCBoireau, AGarret, CJulou, LIn vitro and in vivo inhibition by zopiclone of benzodiazepine binding to rodent brain receptors. Life Sci 1979; 24: 2417–20CrossRefGoogle ScholarPubMed
Blanchard, JCZundel, JLJulou, LDifferences between cyclopyrrolones (suriclone and zopiclone) and benzodiazepine binding to rat hippocampus photolabel led membranes. Biochem Pharmacol 1983; 32: 3651–3CrossRefGoogle Scholar
Bowery, NGDray, AReversal of the action of aminoacid antagonists by barbiturates and other hypnotic drugs. Br J Pharmacol 1978; 63: 197–215CrossRefGoogle ScholarPubMed
Bowery, NGCollins, JFHill, RGPearson, St-Butyl-bicyclophos-phonate: a convulsant and GABA antagonist more potent than bicuculline. Br J Pharmacol 1977; 60: 275P–76PGoogle Scholar
Braestrup, CNielsen, MMultiple benzodiazepine receptors. Trends Neurosci 1980; 3: 301–3CrossRefGoogle Scholar
Braestrup, CNielsen, MBinding of [3H]-methyl-β-carboline-3-car-boxylate to brain benzodiazepine receptors is reduced by GABA. Nature 1981; 294: 472–4CrossRefGoogle Scholar
Braestrup, CSchmiechen, RNeff, GNielsen, MPetersen, ENInteraction of convulsive ligands with benzodiazepine receptors. Science 1982; 216: 1241–3CrossRefGoogle ScholarPubMed
Briley, MSLanger, SZInfluence of GABA receptor agonists and antagonists on the binding of [3H]-diazepam to the benzodia-zepine receptor. Eur J Pharmacol 1978; 52: 129–32CrossRefGoogle Scholar
Brown, CLMartin, ILPhotoaffmity labelling of the benzodiazepine receptor cannot be used to predict ligand efficacy. Neurosci Lett 1983; 35: 37–40CrossRefGoogle ScholarPubMed
Canton, TDoble, AEvidence for different binding domaines on the GABAA/benzodiazepine receptor for benzodiazepines and cyclo-pyrrolones. Clin Neuropharmacol 1992; 15: 620BCrossRefGoogle Scholar
Concas, ASerra, MSantoro, GMaciocco, ECuccheddu, TBiggio, GThe effect of cyclopyrrolones on GABAA receptor function is different from mat of benzodiazepines. Naunyn Schmiedebergs Arch Pharmacol 1994; 350: 294–300CrossRefGoogle Scholar
Depoortere, HZivkovic, BLloyd, KGSanger, DJPerrault, GLanger, SZZolpidem a novel non-benzodiazepine hypnotic. I. Neuro-pharmacological and behavioural effects. J Pharmacol Exp Therap 1986; 237: 649–58Google Scholar
Doble, AComparative thermodynamics of benzodiazepine receptor ligand interactions in rat neuronal membranes. J Neurochem 1983; 40: 1605–12Google ScholarPubMed
Doble, AMartin, ILMultiple benzodiazepine receptors: no reason for anxiety. Trends Pharmacol Sei 1992; 13: 76–81CrossRefGoogle ScholarPubMed
Doble, AMartin, ILRichards, DAGABA modulation predicts biological activity of ligands for the benzodiazepine receptor. Br J Pharmacol 1982; 76: 238PGoogle Scholar
Doble, ACanton, TPiot, OStutzmann, JMZundel, JLCotrel, CBlanchard, JCThe pharmacology of cyclopyrrolone derivatives acting at the GABAA/benzodiazepine receptor. In: Biggio, GConcas, ACosta, E ed. GABAergic synoptic transmission: molecular, pharmacological and clinical aspects New York: Raven Press, 1992 407–18Google Scholar
Doble, ACanton, TDriesler, SPiot, OBoireau, AStutzmann, JM, et al. RP 59037 RP 60503: anxiolytic cyclopyrrolone derivatives with low sedative potential. Interaction with the a-aminobutyric acidA/benzodiazepine receptor complex and behavioural effects in the rodent. J Pharmacol Exp Therap 1993; 266: 1213–26Google Scholar
Haigh, JRMFeely, MTolerance to the anticonvulsant effects of benzodiazepines. Trends Pharmacol Sei 1988; 9: 361–6CrossRefGoogle Scholar
Hu, XJTicku, MKChronic benzodiazepine agonist treatment produces functional uncoupling of the gamma-aminobutyric acid-benzodiazepine receptor ionophore complex in cortical neurons. Mol Pharmacol 1994; 45: 618–25Google ScholarPubMed
Im, WBBlakeman, DPCorrelation between gamma-aminobutyricacid (A) receptor ligand-induced changes in t-butylbicyclophosphoro[35S] thionate binding and 36C1-uptake in rat cerebrocortical membranes. Mol Pharmacol 1991; 39: 394–8Google Scholar
Julou, LBlanchard, JCDreyfus, JFPharmacological and clinical studies of cyclopyrrolones: zopiclone and suriclone. Pharmacol Biochem Behav 1985; 23: 653–9CrossRefGoogle ScholarPubMed
Lloyd, GKDanielou, GThuret, FThe activity of zolpidem and other hypnotics within the a-aminobutyric acid (GABAA) receptor supramolecular complex, as determined by 35S-t-butylbicyclo-phosphothionate binding to rat cerebral cortex membranes. J Pharmacol Exp Therap 1990; 225: 690–6Google Scholar
Malgouris, CPerrot, FDupuis, MKiosseff, TDaniel, MBlanchard, JCDoble, AAutoradiographic distribution of [3H]-suriclone binding sites in the rat brain. Drug Dev Res 1995; 34: 336–43CrossRefGoogle Scholar
Martin, ILCandy, JMFacilitation of benzodiazepine binding by sodium chloride and GABA. Neuropharmacology 1978; 17: 993–8CrossRefGoogle ScholarPubMed
Möhler, HBenzodiazepine receptors: differential interaction of benzodiazepine agonists and antagonists after photoaffmity labelling with flunitrazepam. Eur J Pharmacol 1982; 80: 435–6CrossRefGoogle Scholar
Musch, BMaillard, FZopiclone, the third generation hypnotic: a clinical overview. Int Clin Psychpharmacol 1990; 5: 147–58Google ScholarPubMed
Nutt, DSelective ligands for benzodiazepine receptors: recent developments. In: Osborne, N ed. Current aspects of the Neurosciences Basingstoke: The Macmillan Press, 1990;2:259–93CrossRefGoogle Scholar
Olsen, RWTobin, AJMolecular biology of GABAA receptors. FASEB J 1990; 4: 1469–80CrossRefGoogle ScholarPubMed
Piot, OBetschart, JStutzmann, JMBlanchard, JCCyclopyrrolones, unlike some benzodiazepines, do not induce physical dependence in mice. Neurosci Lett 1990; 117: 140–3CrossRefGoogle Scholar
Pole, PEffects of the selective benzodiazepine antagonist Ro 15-1788 on the cat spinal cord. Experientia 1981; 37: 674Google Scholar
Pole, PMöhler, HHaefely, WThe effect of diazepam on spinal cord activities: possible sites and mechanisms of actions. NS Arch Pharmacol 1974; 284: 319–37Google Scholar
Pritchett, DBLüddens, HSeeburg, PHType I and Type II GABAA-benzodiazepine receptors produced in transfected cells. Science 1989; 245: 1389–92CrossRefGoogle ScholarPubMed
Shapiro, CMMacfarlane, JGMaclean, AWAlleviating sleep-related discontinuance symptoms associated with benzodiazepine withdrawal: a new approach;. JPsychosomKes 1993;37suppl 1:55–7Google ScholarPubMed
Sieghart, WKarobath, MMolecular heterogeneity of benzodiazepine receptors. Nature 1980; 286: 285–7CrossRefGoogle ScholarPubMed
Skerritt, JHMacdonald, RLBenzodiazepine receptor ligand actions on GABA responses. Benzodiazepines, CL 218,872, zopiclone. Eur J Pharmacol 1984; 101: 127–34CrossRefGoogle ScholarPubMed
Squires, RFCasida, JRichardson, MSaederup, E[35S]-t-butyl-bicy-clophosphorothionate binds with high affinity to brain specific receptors coupled to a-aminobutyric acid-A and ion recognition sites. Mol Pharmacol 1983; 23: 326–36Google Scholar
Stutzmann, JMBöhme, GACochon, MRoux, MBlanchard, JCProconflict and electrocorticographic effects of drugs modulating 0GABAergic neurotransmission. Psychopharmacology 1987; 9: 74–9CrossRefGoogle Scholar
Stutzmann, JMLaduron, PMBlanchard, JCPharmacology of new sleep-improving drugs. In: Bunney, WEHippius, HLakmann, GSchmauss, GB ed. Neuropsychopharmacology Berlin: Springer-Verlag, 1990 653–66Google Scholar
Tallman, JFThomas, JWGallagher, DWGABAergic modulation of benzodiazepine binding site sensitivity. Nature 1978; 274: 383–5CrossRefGoogle ScholarPubMed
Trifiletti, RSnyder, SHAnxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors. Mol Pharmacol 1984; 26: 458–69Google ScholarPubMed
Van Voigtlander, PFLewis, RAA rapid screening method for the assessment of benzodiazepine receptor-related physical dependence in mice. Evaluation of benzodiazepine-related agonists and partial agonists. J Pharmacol Meth 1991; 26: 1–5CrossRefGoogle Scholar
Wieland, HALüddens, HSeeburg, PHA single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J Biol Chem 1992; 267: 1426–9Google ScholarPubMed
Wettstein, GSpielman, RBehavioural effects of zopiclone, CL 218,872 and diazepam in squirrel monkeys: antagonism by Ro 15-1788 and CGS 8216. J Pharmacol Exp Therap 1986; 238: 522–8Google Scholar
Wong, GUusi-Oukari, MHansen, HCSuzdak, PDKorpi, ERCharacterization of novel ligands for wild-type and natural mutant diazepam-insensitive benzodiazepine receptors. Eur J Pharmacol 1995; 289: 335–42CrossRefGoogle ScholarPubMed
Zundel, JLBlanchard, JCJulou, LPartial chemical characterisation-suriclone) and benzodiazepines ([3H]- of cyclopyrrolones ([3T] flunitrazepam) binding sites: differences. Life Sci 1985; 36: 2247–55CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.